

Learner Notification

MED Learning Group

Complementary Therapeutic Approaches: Mohs Micrographic Surgery and Immunotherapy in Non-Melanoma Skin Cancer

June 26, 2023

Online

Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Examine clinical trials data supporting the use of new systemic immunotherapy for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation.
2. Describe risk-assessment of patients with NMSCs who may derive greater benefit from new systemic therapies as opposed to Mohs surgery.
3. Review the coordination and collaboration of multidisciplinary team members in the management of patients with advanced NMSCs failing or not amenable to surgery or radiation.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Rashado	Coote	NA
Lisa	Crenshaw	NA
Matthew	Frese	NA
Christina	Gallo	NA
Sylvia	Hanna	NA
Sailesh	Konda	NA
David M.	Miller	Merck, EMD Serono, Regeneron, Sanofi Genzyme, Pfizer, Castle Biosciences, Checkpoint Therapeutics: Scientific/Medical Advisory Board, Checkpoint Therapeutics, Avstera Therapeutics: Stock Shareholder, Regeneron, Kartos Therapeutics, NeoImmuneTech, Project Data Sphere, ECOG-ACRIN Cancer Research Group, the American Skin Association: Research Funding

Vishal Anil	Patel	Almirall, Jounce Therapeutics, PHD Biosciences, Regeneron: Consultant, Regeneron, Sanofi: Speakers Bureau, Science 37: Stock Shareholder
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com